Mpox Vaccine Acceptance in DRC

1 Acceptance of an Mpox Vaccine in the Democratic Republic of the Congo

- 2 Skylar Petrichko¹*, Jason Kindrachuk²*, Dalau Nkamba³, Megan Halbrook¹, Sydney Merritt¹,
- 3 Handdy Kalengi³, Leonard Kamba³, Michael Beya³, Nicole A. Hoff¹, Christophe Luhata⁴, Didine
- 4 K. Kaba^{3#}, Anne W. Rimoin^{1#}
- 5 * Denotes co-first authors. These authors contributed equally to this article.
- 6 # Denotes co-last authors
- 7 Author Affiliation:
- Department of Epidemiology, Jonathan and Karin Fielding School of Public Health,
 University of California, Los Angeles, CA, USA
- Department of Medical Microbiology & Infectious Diseases, Max Rady College of Medicine, University of Manitoba, Winnipeg, MB, Canada
- Kinshasa School of Public Health, University of Kinshasa, Democratic Republic of
 the Congo
- Expanded Programme for Immunization, Ministry of Health, Democratic Republic of
 the Congo
- 16
- 17 *Corresponding Author:*
- 18 Anne W. Rimoin, PhD, MPH
- 19 Professor, Department of Epidemiology, Gordon-Levin Endowed Chair in Infectious Diseases
- 20 and Public Health
- 21 Jonathan and Karin Fielding School of Public Health, University of California, Los Angeles
- 22 650 Charles E. Young Dr, CHS 41-275, Los Angeles, CA, 90095
- 23 +1 (310) 825-2096, arimoin@ucla.edu
- 24
- 25 **KEYWORDS** mpox; vaccination; Democratic Republic of the Congo; MPXV

26

27 WORD COUNTS Abstract - 48; Text - 1289

28

- 29
- 30
- 31
- ~ .
- 32
- 33

Mpox Vaccine Acceptance in DRC

34 ABSTRACT

- 35 We report general acceptance of an mpox vaccine (61.0%) in the Democratic Republic of the
- 36 Congo (n = 5226) with higher acceptance among healthcare workers and respondents in historic
- 37 mpox-endemic regions. These data highlight the need for increased community engagement and
- 38 sensitization before widespread deployment of mpox vaccines.
- 39

40 INTRODUCTION

- 41 Mpox is a zoonotic infectious disease endemic to the Democratic Republic of the Congo (DRC)
- 42 (1-3). In 2022, rapid spread of MPXV Clade IIb worldwide resulted in over 91,000 confirmed
- 43 infections and the declaration of a public health emergency of international concern (PHEIC) (4).
- 44 In the DRC incident cases have quadrupled between 2021 and 2023: over 28,000 suspected cases
- 45 were reported from January 2023 to July 2024, and new introductions recorded in neighboring
- 46 Burundi, Rwanda, Kenya, and Uganda (5). In August 2024 a travel-associated Clade Ib case was
- 47 reported for the first time in Sweden (6). In response to the recent expanding burden of mpox,
- 48 Africa CDC and the WHO declared a Public Health Emergency of Continental Security and
- 49 second PHEIC, respectively.
- 50 Despite the deployment of a modified vaccinia Ankara-Bavarian Nordic vaccine to many high
- and middle-income countries, there currently is no mpox vaccine access for the general
- 52 population in Africa. One vaccination model suggests that vaccination of 80% of children under
- 53 15 years old in DRC would result in robust reductions on morbidity, mortality, and mpox
- 54 circulation (7).

55 METHODS

- 56 The data for this cross-sectional analysis was drawn from a larger longitudinal phone survey
- 57 which began in 2022 and included participants, targeting primarily HCWs, from all 26 provinces
- in the DRC. Participants were selected from historical phone survey records of over 10,000
- 59 persons. From these records, 5,226 adult participants were contacted between December 2023 to
- 60 February 2024 by study staff to complete to this vaccine survey. Surveys were administered via
- 61 phone by trained interviewers in Swahili, French, Lingala, Kikongo, and/or Tshiluba. Survey
- 62 questions included behavioral and social drivers of vaccination and attitudes towards the
- 63 introduction of new vaccines, including mpox. Mpox vaccine acceptance was measured by
- 64 asking participants about their interest in the inclusion of a an mpox vaccine in the national
- 65 vaccination schedule and participants were given several response choices—yes, for either
- adults, children or both; no; and I do not know this disease (Supplementary Material 1). All 'yes'
- 67 responses were collapsed for analysis. Attitudes, vaccine acceptance by province, and
- 68 sociodemographic characteristics were assessed via Likert scale questions and presented as a 5-
- 69 or 3-level variable and chi-square test (α =0.05).
- 70 Ethics approval was provided by the Kinshasa School of Public Health (ESP/CE/188/2023) and
- 71 the University of California, Los Angeles, as a public health response activity designation.

Mpox Vaccine Acceptance in DRC

72 **RESULTS**

- 73 Respondents were predominantly male (79.2%), with the highest percentage from Kwilu
- 74 province (12.6%). There was roughly equivalent representation of those from urban or rural
- settings. Most respondents reported some college/university education (41.2%) and identified as
- 76 healthcare workers (55.5%) (Table 1).

77 Participants generally disagreed with the statement that new vaccines carry more risks than older

- vaccines. However, in four provinces—Sud Kivu, Nord Ubangi, Nord Kivu, and Lualaba—more
- than 50% of respondents agreed with or felt that greater risks exist. Respondents generally
- 80 agreed with the statement that information received about vaccines from the vaccination program
- 81 was reliable and trustworthy. In Sankuru province, 29.5% of respondents felt neutral about the
- 82 reliability of vaccine program information; Haut Katanga and Lomami had the highest
- prevalence of vaccine information distrust, with 7.6% and 6.8% disagreeing with the statement.
- 84 (Figure 1).
- Nationally, there was general acceptance of an mpox vaccination by all respondents (61.0%, 95%
- 86 CI:59.6-62.4); 21.7% had no interest, and 17.3% reported no knowledge of mpox. At the
- provincial level, more than 80% of respondents from Kwango, Tshuapa, Nord Ubangi,
- 88 Tanganyika, and Maniema were accepting of a vaccine, while respondents from Sankuru had the
- 89 lowest acceptance (19.9%, 95% CI:14.3-26.6). Sankuru also had the highest percentage of
- 90 participants that reported no mpox knowledge (57.4%, 95% CI:49.7-64.8). In general, rates of
- 91 mpox vaccine acceptance and mpox disease knowledge were not influenced by the history of
- 92 mpox cases within the province (Figure 2).
- 93 Mpox vaccine acceptance varied significantly by province (p <0.0001). When stratified by
- 94 educational attainment, those with a high school diploma had significantly lower acceptance of
- the mpox vaccine (49.8% 95%CI: 47.3-52.3) compared with others. Of all occupations reported,
- 96 healthcare workers had the highest acceptance rates (69.4%, 95% CI: 67.6-71.1). Respondents
- 97 from rural locations indicated greater acceptance of mpox vaccine deployment than their urban
- 98 counterparts (64.4% vs 57.7%, p<0.0001). Among respondents who reported receiving a
- 99 COVID-19 vaccine (n=4396), 63.2% indicated mpox vaccine acceptance. Additionally, persons
- 100 who reported experiencing no chronic conditions reported higher rates of mpox vaccine
- 101 acceptance (62.2% vs 51.0%) (Figure 3).
- 102

103 CONCLUSION

104 Given the ongoing escalation of the concurrent DRC Clade Ia and Clade Ib outbreaks and recent

105 identification of cases in adjacent countries in Central Africa, there is increasing need for the

106 rapid introduction of an mpox vaccine. However, to date, there is a paucity of information

- 107 regarding mpox vaccine acceptance and mpox knowledge across DRC. We observed greater
- 108 interest in mpox vaccine deployment among respondents from rural locations compared with
- 109 urban populations. This is perhaps explained by the historic burden of mpox in DRC as mpox

Mpox Vaccine Acceptance in DRC

- 110 cases were primarily identified among children in rural regions. Currently, reported mpox cases
- 111 are rising in urban centers, further challenging response and vaccine planning efforts.
- 112 Assessing mpox vaccine trust and acceptance across provinces that have and have not
- 113 experienced mpox cases, and across demographic variables did not yield clear or neatly
- described trends. Instead, we observed several instances of outliers that may reflect the
- uniqueness and diversity of the DRC. For example, differing vaccine acceptance rates between
- those with and without chronic conditions may indicate underlying health anxieties among those
- 117 with persistent health problems; further investigation is needed to better understand this
- relationship. Additionally, Sankuru province was consistently a vaccine hesitant outlier. Sankuru
- had the lowest proportion of respondents who trust information received from national vaccine
- programs and the lowest mpox vaccine acceptance, primarily because 57.4% of respondents
- stated no knowledge of mpox. In DRC, the majority of mpox endemic provinces consist of
- rainforest or forest-savannah mosaic geographies; the southeast provinces are primarily savanna
- and grassland and with no history of reported mpox cases. However, in June 2024 Lualaba
- reported their first mpox case. Interestingly, this province had the highest proportion of
- respondents believing that new vaccines have greater risks than older vaccines, though overall
- 126 trust in national vaccine programs was high.
- 127 While these results report an overall trend of vaccine trust and acceptance nation-wide, they also
- 128 indicate the need for a multifaceted approach to vaccine education and rollout. Strategies should
- be tailored to historically endemic regions and/or areas with lower vaccine acceptance, such as
- 130 Sankuru or Kasai Central, and consider how personal experiences and cultural considerations
- 131 intersect with mpox outbreaks. Of note, Haut Lomami province has been the setting of long-
- standing routine immunization revitalization efforts (8, 9), and 100% of respondents from this
- 133 province reported that they feel information from the national vaccine program is reliable. This
- highly positive response is perhaps reflective of the many years of vaccine campaigns and
- education efforts in this region.
- 136 This survey was limited to those with access to phones; individuals with a lower socioeconomic
- 137 status may have been inadvertently excluded from this study, including those in largely rural
- regions. This study included respondents from all provinces in DRC, with an emphasis on
- 139 recruiting HCW. Past studies in the DRC have demonstrated 54% acceptance towards outbreak-
- 140 related vaccines, with HCW continually expressing the highest acceptance among all
- 141 respondents (10). As this study sought to enroll HCWs, and community and religious leaders, we
- 142 observed an over-representation of men as they primarily hold these leadership roles in the DRC.
- 143 As HCWs and religious leaders serve as health recommenders for their communities, there is a
- 144 critical need to identify and address vaccine acceptance among these groups. These data provide
- 145 insight regarding future deployments in adjacent regions as well as vaccine acceptance and
- 146 deployment strategies within DRC, or regionally, for other emerging infectious diseases.
- 147
- 148
- 149

Mpox Vaccine Acceptance in DRC

150 ACKNOWLEDGEMENTS

- 151 All cartographic figures were generated using qGIS (Maidenhead, 3.36.3). We thank Brooke
- 152 Aksnes and Emma Wray Aberle-Grasse for their continued support of this ongoing research
- 153 endeavor.
- 154

155 FUNDING

- 156 This work was supported by funding from the Centers for Disease Control and Prevention (CDC)
- 157 through the Task Force for Global Health (TFGH) under Cooperative Agreement # 6
- 158 NU2RGH001916-02-06. The content of the information does not necessarily reflect the position
- 159 or the policy of TFGH, and no official endorsement should be inferred.
- 160

161 **REFERENCES**

- 162 1. AI B. Human monkeypox, 1970-79. Bull World Health Organ. 1980;58:165182.
- 163 2. Foster SO, Brink EW, Hutchins DL, Pifer JM, Lourie B, Moser CR, et al. Human
- 164 monkeypox. Bull World Health Organ. 1972;46(5):569-76.
- 165 3. Ladnyj ID, Ziegler P, Kima E. A human infection caused by monkeypox virus in
- 166 Basankusu Territory, Democratic Republic of the Congo. Bull World Health Organ.
- 167 1972;46(5):593-7.
- 168 4. (WHO) WHO. Mpox (monkeypox) Outbreak. Emergencies 2024 [cited 2024; Available
 169 from: <u>https://www.who.int/europe/emergencies/situations/monkeypox</u>
- 170 5. (SGI-MPOX) SdGdLEM. Epidemie de Mpox en Republique Democratique du Congo;
 171 Rapport de Situation No. 027. Kinshasa, DRC: Institut National de Sante Publique; 2024.
- 172 6. Mpox due to monkeypox virus clade I. Epidemiological Update: European Center for
- 173 Disease Prevention and Control (ECDC); 2024.
- Savinkina A, Kindrachuk J, Bogoch I, Rimoin AW, Hoff NA, Shaw SY, et al. Modeling
 Vaccination Approaches for Mpox Containment and Mitigation in the Democratic Republic of
 the Congo. Available at SSRN 4759169. 2024.
- 177 8. Lame P, Milabyo A, Tangney S, Mbaka GO, Luhata C, Gargasson JL, et al. A Successful
- 178 National and Multipartner Approach to Increase Immunization Coverage: The Democratic
- 179 Republic of Congo Mashako Plan 2018-2020. Glob Health Sci Pract. 2023 Apr 28;11(2).
- 180 9. Banza Mpiongo P, Kibanza J, Kambol Yav F, Nyombo D, Mwepu L, Basame D, et al.
- 181 Strengthening immunization programs through innovative sub-national public-private
- partnerships in selected provinces in the Democratic Republic of the Congo. Vaccine. 2023
 2023/12/12/;41(51):7598-607.
- 184 10. Peckeu-Abboud L, Mangoni P, Chammam K, Kwete P, Mutombo Lupola P, Vanlerberghe
 185 V, et al. Drivers of routine and outbreak vaccination uptake in the western Democratic Republic
 186 of Congo: an exploratory study in ten health zones. Vaccines. 2022;10(7):1066.
- 187
- 188

189 FIGURES AND TABLES

Mpox Vaccine Acceptance in DRC

Table 1. Demographic Characteristics of National Phone Survey Respondents (n = 5226)

	Fre	Frequency	
Sample characteristic ¹	n	= 5226	
Demographics			
Age (median [IQR])	42	16.0	
Gender			
Male	4138	(79.2%)	
Female	1088	(20.8%)	
Education Level			
Less than high school	359	(6.9%)	
Graduated high school	1589	(30.4%)	
Some college	2158	(41.3%)	
Bachelor or advanced degree	1120	(21.4%)	
Province			
Maindombe	134	(2.6%)	
Kwango	183	(3.5%)	
Kwilu	657	(12.6%)	
Kongo Central	312	(6.0%)	
Equateur	162	(3.1%)	
Mongala	238	(4.6%)	
Tshuapa	63	(1.2%)	
Nord Ubangi	113	(2.2%)	
Sud Ubangi	91	(1.7%)	
Kasai Oriental	597	(11.4%)	
Sankuru	176	(3.4%)	
Lomami	192	(3.7%)	
Kasai	118	(2.3%)	
Kasai Central	87	(1.7%)	
Haut Katanga	331	(6.3%)	

Mpox Vaccine Acceptance in DRC

Tanganyika	151	(2.9%)
Haut Lomami	50	(1.0%)
Lualaba	168	(3.2%)
Kinshasa	251	(4.8%)
Maniema	98	(1.9%)
North Kivu	140	(2.7%)
Bas Uele	246	(4.7%)
Haut Uele	137	(2.6%)
Ituri	239	(4.6%)
Tshopo	144	(2.8%)
Sud Kivu	148	(2.8%)
Geographic Area		
Urban	2659	(50.9%)
Rural	2567	(49.1%)
Occupation		
Health worker	2899	(55.5%)
Religious leader	89	(1.7%)
Community or essential services leader	768	(14.7%)
Public service sector or educator	670	(12.8%)
Other worker	513	(9.8%)
Not working	287	(5.5%)
Health Information		
Health conditions		
Chronic lung disease	32	(0.6%)
Diabetes	209	(4.0%)
Cardiovascular disease	254	(4.9%)
Chronic renal disease	12	(0.2%)
Chronic liver disease	9	(0.2%)
Immunocompromised	10	(0.2%)

Mpox Vaccine Acceptance in DRC

No conditions	4700	(89.9%)

¹Reported as n (%) unless otherwise noted.

²Abbreviations: IQR, Interquartile range

191

- **192** Figure 1. General Vaccine Attitudes and Perceptions by Province. (A) Reported responses to
- the statement "New vaccines carry more risks than older vaccines" (B) Reported responses to the statement "Information I receive about vaccines from the vaccine program is reliable and
- 195 trustworthy". 3-level responses were collapsed from a 5-point Likert scale.

196



Mpox Vaccine Acceptance in DRC

- adults only" (B) Reported non-acceptance by the response "No, not interested". (C) Reported
- 208 lack of knowledge of mpox disease. Percentages are reported by province.
- 209 (A)



Mpox Vaccine Acceptance in DRC

Historical Mpox Cases



Kasa

ango

Kasaï-Centra Kasaï-Orienta Lomami

Haut-Loma

Luala

Tanganyika

Hau -Katanga

Kongo-Central

- 215
- 216
- 217

218 Figure 3. Percent of Mpox Vaccine Acceptance by Province and Demographic

- Characteristic. Acceptance of an Mpox Vaccine among respondents as stratified by 219
- sociodemographic characteristics and known mpox risk factors COVID-19 vaccination was 220
- dichotomized by whether the respondent received the COVID-19 vaccine. Health condition was 221
- dichotomized based on whether the respondent stated they had a chronic disease or were 222
- immunocompromised. 223
- * Chi-sq p-value <.05 224

Mpox Vaccine Acceptance in DRC

Characteristic	n					Percent (95% CI)
*Province						
Bas Uele	125		-	•		50.8 (44.6 to 57.0)
Equateur	77					47.8 (40.2 to 55.6)
Haut Katanga	141					66.8 (60.2 to 72.9)
Haut Lomami	20					40.8 (27.9 to 55.1)
Haut Uele	107				.	78.1 (70.4 to 84.3)
Ituri	134			— —		56.3 (49.9 to 62.5)
Kasai	80					67.8 (58.8 to 75.6)
Kasai Central	32					37.6 (28.0 to 48.4)
Kasai Oriental	416			-	•	70.7 (66.9 to 74.3)
Kinshasa	182			-	- - -	72.8 (66.9 to 78.0)
Kongo Central	109					35.3 (30.1 to 40.8)
Kwango	154					84.2 (78.1 to 88.8)
Kwilu	375					58.3 (54.5 to 62.1)
Lomami	102		-			53.7 (46.5 to 60.7)
Lualaba	92					56.1 (48.4 to 63.5)
Maindombe	82				-	61.7 (53.1 to 69.5)
Maniema	84					85.7 (77.3 to 91.4)
Mongala	176				- - -	73.9 (68.0 to 79.1)
Nord Ubangi	95					84.1 (76.1 to 89.7)
North Kivu	85					60.7 (52.4 to 68.5)
Sankuru	35					19.9 (14.6 to 26.5)
Sud Kivu	82		-			55.8 (47.6 to 63.6)
Sud Ubangi	45			•		51.7 (41.2 to 62.1)
Tanganyika	129					85.4 (78.8 to 90.2)
Tshopo	74		_	•		51.4 (43.2 to 59.5)
Tshuapa	55					87.3 (76.5 to 93.6)
		20	40	60	80	100

Characteristic	n		Percent (95% CI)
Gender			
Female	609		58.5 (55.5 to 61.5)
Male	2479	-	- 61.7 (60.1 to 63.1)
*Education			
Less than high school	215		60.9 (55.7 to 65.9)
Graduated high school	767		49.8 (47.3 to 52.3)
Some college	1391		66.7 (64.6 to 68.6)
Bachelor or advanced degree	715		66.1 (63.3 to 68.9)
*Occupation			
Health worker	1947		69.4 (67.7 to 71.1)
Community leader	364	_ -	48.3 (44.7 to 51.8)
Public Servant or Educator	330	-	50.8 (46.9 to 54.6)
Religious leader	40		44.9 (34.9 to 55.4)
Other worker	287		- 58.8 (54.4 to 63.1)
Not working	120	-	43.6 (37.9 to 49.6)
*Geographic Area			
Rural	1616		64.4 (62.5 to 66.2)
Urban	1472		57.7 (55.8 to 59.6)
*COVID-19 Vaccination			
No	311		46.8 (43.0 to 50.6)
Yes	2777	-	 63.2 (61.7 to 64.6)
*Health Condition			
No	2815	-	← 62.2 (60.8 to 63.6)
Yes	273		51.0 (46.8 to 55.3)
	3) 40 50 60	70 80

225